264 related articles for article (PubMed ID: 17662154)
1. Analysis of the cellular centrosome in fine-needle aspirations of the breast.
Guo HQ; Gao M; Ma J; Xiao T; Zhao LL; Gao Y; Pan QJ
Breast Cancer Res; 2007; 9(4):R48. PubMed ID: 17662154
[TBL] [Abstract][Full Text] [Related]
2. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
3. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
4. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
Titi S
Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
Hoff ER; Tubbs RR; Myles JL; Procop GW
Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
[TBL] [Abstract][Full Text] [Related]
7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
8. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
Lewis JT; Ketterling RP; Halling KC; Reynolds C; Jenkins RB; Visscher DW
Am J Clin Pathol; 2005 Aug; 124(2):273-81. PubMed ID: 16040300
[TBL] [Abstract][Full Text] [Related]
9. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
[TBL] [Abstract][Full Text] [Related]
10. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
12. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
15. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors.
Tse GM; Cheung HS; Pang LM; Chu WC; Law BK; Kung FY; Yeung DK
AJR Am J Roentgenol; 2003 Nov; 181(5):1267-72. PubMed ID: 14573418
[TBL] [Abstract][Full Text] [Related]
16. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
17. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
Lin F; Shen T; Prichard JW
Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
Heintz NH; Leslie KO; Rogers LA; Howard PL
Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
[TBL] [Abstract][Full Text] [Related]
19. Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.
Niu Y; Wang S; Liu T; Zhang T; Wei X; Wang Y; Jiang L
Pathol Res Pract; 2013 Apr; 209(4):221-7. PubMed ID: 23523041
[TBL] [Abstract][Full Text] [Related]
20. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]